Actelion: Delivering well on schedule

A new FV of CHF156 derives from revised assumptions with Opsumit as it should take fewer years than we anticipated to reach peak sales. The investment case is very much valid post Q3 numbers.

For more information, please contact marketing@bryangarnier.com